October 21, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome
 

Tokyo, Feb 22, 2013 (JCN) - Otsuka Pharmaceutical Co., Ltd. announced the launch of 'Neupro Patch' (chemical name: rotigotine) for both the treatment of Parkinson's disease and Restless Legs Syndrome in Japan, beginning on February 26, 2013.

Neupro Patch is the only transdermal dopamine agonist system available in the world, which only needs to be applied once a day, enabling a clinically-effective blood drug concentration via stable drug delivery throughout a 24-hour period.

Approximately 140,000 Parkinson's disease patients are estimated to be living in Japan, and those with progressive disease are more likely to experience drug efficacy diminishing or ceasing during certain times of the day, and as a result their daily living activities are affected.

These patients often experience the difficulty and inconvenience of drug efficacy diminishing or ceasing during late evening or early in the morning, manifesting their symptoms. As a result, patients are often sleep-deprived, which further affects their performance the following morning.

Patients often find it distressing not being able to spend their mornings actively, since even basic activities such as going to the toilet, getting dressed, and taking meals, are affected.

Neupro Patch is expected to provide relief for both patients and their caregivers, as it needs to be applied only once daily in order to achieve a stable blood drug concentration for 24 hours.

Restless Legs Syndrome is characterized by abnormal sensations, particularly in patients' calves, thighs and feet. Patients are not able to stay still due to these unpleasant sensations which are often expressed as creeping, itchy, or prickly feelings within or around the legs, although the expression varies from patient to patient. These sensations are felt at rest in the evening, such as at bedtime, and are known to prevent sound sleep.

Patients with Restless Legs Syndrome may also suffer when sedentary during daytime hours as well. Neupro Patch can alleviate Restless Legs Syndrome symptoms throughout the day via simple application of a once-a-day patch which delivers a stable dopaminergic treatment lasting for 24 hours.

Otsuka Pharmaceutical acquired in 2002 the exclusive rights for developing and marketing Neupro Patch in Japan. Outside of Japan, the drug is known as Neupro, marketed in 35 countries by the product's owner, UCB, the global biopharmaceutical company based in Belgium.

By Chris Lui Staff Writer

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Otsuka Pharmaceutical Co., Ltd. News  
  Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information  (Oct 14, 2014)
  Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome  (Feb 22, 2013)
  Pocari Sweat Launches in Vietnam  (Aug 1, 2012)
  Otsuka Pharmaceutical, UCB to Focus Collaboration on Central Nervous System Disorders  (Jan 19, 2012)
  Iwamoto Becomes Otsuka Pharmaceutical President  (June 26, 2008)
  Otsuka Pharm. to Acquire 49 Pct of French Beverage Maker Alma  (May 28, 2008)
  Otsuka to Pay 4 M. Dollars to Settle Off-Label Charges in U.S.  (Mar 28, 2008)
  Bristol-Myers Squibb and Otsuka Pharmaceutical Announce Exclusive Licensing Agreement for Diabetes compund Saxagliptin in Japan  (Dec 27, 2006)
  Otsuka Pharmaceutical and Chugai Pharmaceutical Announce Antiplatelet Agent Pletaal(R) Co-Promotion Agreement  (Dec 12, 2006)
  Otsuka Pharmaceutical and Chugai Pharmaceutical Announce Antiplatelet Agent Pletaal(R) Co-Promotion Agreement  (Dec 12, 2006)



 Recent  Drugs & OTC News   
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)

More Drugs & OTC news...

 Recent  Medical News   
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)

More Medical news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)